Long-term outcomes in patients with aortic stenosis and transthyretin cardiac amyloidosis
No Thumbnail Available
Authors
Patel, Kush P.
Autherith, Maximilian
Scully, Paul R.
Koschutnik, Matthias
Katsoulis, Michail
Dona, Carolina
Kronberger, Christina
Halavina, Kseniya
Hauptmann, Laurenz
Bartko, Philipp
Contact
Check for full-text access
Issue Date
2026
Type
Article
Language
Keywords
Alternative Title
Abstract
BACKGROUND: The coexistence of aortic stenosis (AS) and transthyretin cardiac amyloidosis (CA) is common. If treated with transcatheter aortic valve replacement (TAVR), patients with the combined phenotype (AS-CA) have a similar survival at 1 year compared to those with lone AS. This study aims to evaluate the long-term outcomes of AS-CA compared to lone AS. METHODS: Using a prospective, multicenter, observational, case-control design, we studied patients with severe AS referred for TAVR. All underwent bone scintigraphy to differentiate between AS-CA and lone AS. Outcomes were compared between the two cohorts. Mortality (all-cause and cardiovascular [CV]) and hospitalization for heart failure (HHF) were captured as clinical endpoints for long-term outcome. RESULTS: 406 patients [84(80-88) years, 50 % female, EuroSCORE-II 4.2 (3.7-5.0)] were recruited, of which 47 (11.6 %) had AS-CA (all transthyretin). Over a follow-up of 5.4 (4.9-5.8) years, 244 (60.1 %) patients died. AS-CA was associated with higher all-cause mortality (crude HR 1.75, 95 % CI 1.24-2.46; log-rank, p = 0.001), which remained significant after multivariate adjustment for clinical confounders (EuroSCORE-II, valve replacement; adjusted HR 1.72, 95 % CI 1.22-2.42; p = 0.002). AS-CA was not associated with CV mortality (log-rank, p = 0.18) or time to first HHF (log-rank, p = 0.43), but the rate of HHF was significantly higher in AS-CA compared to lone AS (129 versus 65 per 1000 patient years, p = 0.022). CONCLUSION: AS-CA is associated with an increased long-term risk of all-cause mortality and rate of hospitalization for heart failure compared to patients with AS. Further studies evaluating the role of CA-specific therapies are warranted in this population.
Description
Citation
Publisher
License
Journal
International journal of cardiology
Volume
449